Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023736%3A_____%2F16%3A00011550" target="_blank" >RIV/00023736:_____/16:00011550 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/16:00092596 RIV/65269705:_____/16:00066093

Výsledek na webu

<a href="http://dx.doi.org/10.1038/leu.2016.90" target="_blank" >http://dx.doi.org/10.1038/leu.2016.90</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1038/leu.2016.90" target="_blank" >10.1038/leu.2016.90</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale

Popis výsledku v původním jazyce

Molecular monitoring of chronic myeloid leukemia patients using robust BCR-ABL1 tests standardized to the International Scale (IS) is key to proper disease management, especially when treatment cessation is considered. Most laboratories currently use a time-consuming sample exchange process with reference laboratories for IS calibration. A World Health Organization (WHO) BCR-ABL1 reference panel was developed (MR 1 -MR 4), but access to the material is limited. In this study, we describe the development of the first cell-based secondary reference panel that is traceable to and faithfully replicates the WHO panel, with an additional MR 4.5 level. The secondary panel was calibrated to IS using digital PCR with ABL1, BCR and GUSB as reference genes and evaluated by 44 laboratories worldwide.

Název v anglickém jazyce

Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale

Popis výsledku anglicky

Molecular monitoring of chronic myeloid leukemia patients using robust BCR-ABL1 tests standardized to the International Scale (IS) is key to proper disease management, especially when treatment cessation is considered. Most laboratories currently use a time-consuming sample exchange process with reference laboratories for IS calibration. A World Health Organization (WHO) BCR-ABL1 reference panel was developed (MR 1 -MR 4), but access to the material is limited. In this study, we describe the development of the first cell-based secondary reference panel that is traceable to and faithfully replicates the WHO panel, with an additional MR 4.5 level. The secondary panel was calibrated to IS using digital PCR with ABL1, BCR and GUSB as reference genes and evaluated by 44 laboratories worldwide.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2016

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Leukemia

ISSN

0887-6924

e-ISSN

—

Svazek periodika

30

Číslo periodika v rámci svazku

9

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

9

Strana od-do

1844-1852

Kód UT WoS článku

000383786400021

EID výsledku v databázi Scopus

—